ReviewWorld journal of urology2020
Management of Peyronie's disease with collagenase Clostridium histolyticum in the acute phase.
Review in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Comment on: Targeting the acute phase of Peyronie's disease: preliminary experience with Perovial®, a novel hyaluronic acid formulation.International journal of impotence research · 2026Article
- Targeting the acute phase of Peyronie's disease: preliminary experience with Perovial®, a novel hyaluronic acid formulation.International journal of impotence research · 2025Review
- Cost Consideration for the Treatment of Peyronie's Disease: A Narrative Review.Current urology reports · 2025Review
- Comparative outcomes of intralesional collagenase injection for Peyronie's disease: acute vs. stable phase treatment.International journal of impotence research · 2025Article
- A review of Peyronie's disease insurance coverage.Sexual medicine · 2024Article
- Conservative treatment of Peyronie's disease: a guide.World journal of urology · 2024Review
- In Vitro Study of a NovelCells · 2023Article
- Improvement in the ability to have sex in patients with Peyronie's disease treated with CollagenaseBJUI compass · 2023Article
- Intralesional collagenaseTranslational andrology and urology · 2022Article
- Home modeling after penile prosthesis implantation in the management of residual curvature in Peyronie's disease.International journal of impotence research · 2021Article
- Comparison of Intralesional Hyaluronic AcidThe world journal of men's health · 2021Article
- Peyronie's disease - outcomes of collagenaseArab journal of urology · 2021Review
- Efficacy of Collagenase Clostridium histolyticum (XiapexClinical drug investigation · 2020Article
- Peyronie's disease in contemporary urological practice.World journal of urology · 2020Article
- Intraoperative methods for residual curvature correction during penile prosthesis implantation in patients with Peyronie's disease and refractory erectile dysfunction.International journal of impotence research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPeyronie's disease (PD) can affect men of all ages and is associated with penile pain as well as curvature and erectile dysfunction. Treatment modalities for PD include conservative, less invasive and surgical treatments. Choice of treatment depends on the disease's phase. Injection of collagenase Clostridium histolyticum (CCH) is only the Food and Drug Administration approved treatment for the management of the chronic phase of the disease. Only a few limited studies have evaluated its potential benefits during the acute phase.
aimTo evaluate the current evidence on the use of injectable CCH during the acute or active phase of PD.
methodsWe performed a PubMed database search for articles published between 2015 and 2018 that investigated the use of CCH for the management of the acute phase of PD. Search keywords included "Peyronie's disease", "collagenase Clostridium histolyticum", and "acute phase".
main outcome measuresChanges in penile curvature after treatment with injectable CCH.
resultsMean curvature decrease ranged between 15.8° and 22.6° corresponding to 27.4-37.4% decrease from baseline after 2.5-4 cycles, corresponding to 5-8 injections, of CCH treatment in patients during the acute phase of PD.
conclusionsIntralesional CCH injection therapy during the acute phase of PD can be both safe and effective and clinically significant improvements in penile curvature may be achieved. Larger multi-institutional studies are, however, still needed to confirm these results and validate this additional indication for CCH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.